胰腺癌患者接受新辅助或姑息性FOLFIRINOX治疗后转化手术的预测因素:基于基线和随访CT
该回顾性研究纳入189例接受超过4周期FOLFIRINOX的胰腺腺癌患者,通过基线、首次随访及术前/末次随访CT评估肿瘤大小变化、胰腺外神经侵犯及可切除性。结果显示基线可切除、首次随访CT部分缓解及基线交界可切除是转化手术的重要预测因素,肿瘤缩小cut-off为22.2%时AUC为0.761。
要点
- 基线交界可切除、末次CT可切除状态及首次随访CT部分缓解是转化手术的重要预测因素。
- 肿瘤缩小cut-off为22.2%时,预测转化手术的AUC为0.761,敏感度70.3%,特异度74.8%。
- 局部晚期亚组中,首次随访CT部分缓解预测转化手术的AUC为0.914,敏感度100%,特异度75%。
核心结论
- 基线和随访CT表现均有助于预测胰腺腺癌患者接受FOLFIRINOX后的转化手术。
研究设计与样本
- 回顾性纳入189例接受超过4周期FOLFIRINOX的胰腺腺癌患者,复习基线CT、首次随访CT及术前或末次随访CT,依据RECIST 1.1评估肿瘤大小变化,评估胰腺外神经侵犯及NCCN 2019指南可切除性,并按基线可切除性进行亚组分析。
诊断标准与关键数值
- 末次CT可切除状态预测手术的HR为65.5(95%CI 5.0-865,P=0.002)。
- 首次随访CT RECIST部分缓解预测手术的HR为3.6(95%CI 1.1-11.7,P=0.032)。
- 基线交界可切除预测手术的HR为8.6(95%CI 1.6-46.4,P=0.013)。
- 肿瘤缩小cut-off为22.2%时,预测手术的AUC为0.761,敏感度70.3%,特异度74.8%。
- 局部晚期亚组中,首次随访CT部分缓解预测手术的HR为32(95%CI 4.5-227,P=0.001),最佳cut-off为22.2%,AUC为0.914,敏感度100%,特异度75%。
临床应用与阅片要点
- 基线可切除性、首次随访CT的RECIST部分缓解及末次CT可切除状态可用于预测转化手术可能。
- 局部晚期患者中,首次随访CT部分缓解对转化手术有较高预测价值。
- 基线肿瘤大小≥4 cm(HR 5.6,95%CI 1.3-24.3,P=0.022)及首次随访CT不可切除状态(HR 4.8,95%CI 1.1-20.6,P=0.035)与切缘阳性切除显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: We aimed to evaluate the predictive factors of conversion surgery in pancreatic adenocarcinoma (PAC) after neoadjuvant or palliative FOLFIRINOX using baseline and follow-up CT.
METHODS: We retrospectively included 189 patients who had undergone more than 4 cycles of FOLFIRINOX. We reviewed baseline CT (B-CT), 1st follow-up CT (1st-CT), and the preoperative or last follow-up CT (L-CT) and determined tumor size changes according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Extra-pancreatic perineural invasion (EPNI) and resectability using NCCN 2019 guideline were evaluated. Subgroup analysis by baseline resectability was performed.
RESULTS: B-CT included resectable (n = 25, 23.2%), borderline (n = 55, 29.1%), locally advanced (n = 44, 23.3%), and metastatic (n = 65, 34.4%) PAC. Seventy-four patients had undergone surgery (39.2%) with an 83.8% (62/74) R0 resection. For operability, resectable status at L-CT (hazard ratio (HR) 65.5; 95% confidence interval (CI) 5.0-865; P = 0.002), RECIST (partial response) at 1st-CT (HR 3.6; 95% CI 1.1-11.7; P = 0.032), and baseline borderline resectability (HR 8.6; 95% CI 1.6-46.4; P = 0.013) were important predictors. Based on a size reduction cut-off of 22.2%, the area under the receiver operating characteristic (ROC) curve (Az) was 0.761 (sensitivity = 70.3%, specificity = 74.8%). In subgroup analysis, RECIST (partial response) at 1st-CT was a significant predictor of locally advanced PAC (HR 32; 95% CI 4.5-227, P 0.001), and the optimal cut-off was 22.2% (Az = 0.914; sensitivity = 100%, specificity = 75%). Baseline tumor size ([Formula: see text] 4 cm) (HR 5.6, 95% CI 1.3-24.3, P = 0.022) and unresectable status at 1st-CT (HR 4.8, 95% CI 1.1-20.6, P = 0.035) were significantly associated with margin-positive resection.
CONCLUSION: Both baseline and follow-up CT findings are useful to predict conversion surgery for PAC after FOLFIRINOX.
引用
- Park SJ, Kim JH, Joo I, et al. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. Abdom Radiol (NY). 2021. PMID: 34085090. doi:10.1007/s00261-021-03127-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。